Consumer Reports
A growing number of blushwood berry extract users are reporting improvements in joint pain and mobility, adding to an evolving body of consumer-reported outcomes.
Human Trials
Phase I trial data shows that wound healing after intratumoral EBC-46 injection follows a predictable pattern, with most treated sites closing within four to six weeks.
Mechanism of Action
EBC-46 triggers rapid neutrophil infiltration at the injection site, creating a localised inflammatory response that accelerates tumour clearance within hours.
Regulatory
The FDA botanical drug pathway offers a unique regulatory route for plant-derived compounds like EBC-46, with specific IND requirements that differ from synthetic drugs.
consumer-reports
Blushwood berry extract users increasingly report applying it to warts, sebaceous cysts, and skin tags. Here's what those reports show, and where the science is plausible versus speculative.
human-trials
How do EBC-46 trial investigators decide whether a treatment worked? The answer lies in RECIST 1.1 criteria and the specific challenges of measuring response in intratumoral therapy.
mechanism-of-action
EBC-46's activation of protein kinase C does more than disrupt tumour vasculature — it may also suppress NF-κB, one of cancer's most critical survival signalling pathways.
Regulatory
The FDA's Accelerated Approval pathway could allow tigilanol tiglate to reach patients before full Phase III data is available — here's how surrogate endpoints make that possible.
EBC-46
EBC-46 mimics the natural lipid messenger diacylglycerol to activate specific PKC isoforms — a molecular trick that explains its targeted anti-tumour effects.
EBC-46
Compassionate use and expanded access programmes could allow terminal patients to receive tigilanol tiglate before regulatory approval is finalised.
EBC-46
When doctors start looking up Blushwood berry themselves after reviewing patient blood work, the anecdotal becomes harder to ignore.
EBC-46
Tigilanol tiglate is the headline compound — but the full phytochemical profile of Fontainea picrosperma remains largely uncharacterised, and that may matter enormously.